fomesafen has been researched along with Multiple Sclerosis, Chronic Progressive in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Aragona, M; Bettolo, CM; Conte, A; Frasca, V; Gabriele, M; Giacomelli, E; Gilio, F; Iacovelli, E; Inghilleri, M; Onesti, E; Pantano, P; Pozzilli, C; Tomassini, V | 1 |
Cakmur, R; Genc, A; Idiman, E; Idiman, F; Tataroglu, C | 1 |
2 trial(s) available for fomesafen and Multiple Sclerosis, Chronic Progressive
Article | Year |
---|---|
Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis.
Topics: Administration, Oral; Adult; Afferent Pathways; Analgesics; Cannabinoids; Central Nervous System; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Neural Conduction; Nociceptors; Pain; Pain Measurement; Pain Threshold; Placebos; Reaction Time; Reflex; Treatment Outcome | 2009 |
Cortical relay time for long latency reflexes in patients with definite multiple sclerosis.
Topics: Adolescent; Adult; Cerebral Cortex; Disability Evaluation; Evoked Potentials, Motor; Evoked Potentials, Somatosensory; Female; Humans; Male; Middle Aged; Multiple Sclerosis, Chronic Progressive; Multiple Sclerosis, Relapsing-Remitting; Reaction Time; Reflex; Severity of Illness Index; Time Factors | 2004 |